Accendra Health (Formerly Owens & Minor) Discloses Executive Pay

Why It Matters

The filing shows how a med‑tech leader rewards its executives amid a major divestiture and under‑performance, and the widening pay gap could trigger heightened shareholder scrutiny.

Key Takeaways

• CEO Ed Pesicka earned $11.2 M in 2025, up 4%.
• CFO Jonathan Leon compensation rose 30% to nearly $3 M.
• Median employee salary $41,005, CEO‑pay ratio 272:1.
• P&HS sale to Platinum Equity valued at $375 M.
• Shareholders face a May 14, 2026 say‑on‑pay vote.

Pulse Analysis

Accendra Health, the former Owens & Minor, completed a $375 million sale of its Products & Healthcare Services (P&HS) unit to private‑equity firm Platinum Equity at the end of 2025 and rebranded on Dec. 31, 2025. The divestiture removed a $10.7 billion revenue stream that had underperformed, leaving the company with $10.672 billion in 2025 revenue, slightly below its target. In its SEC filing the company disclosed 2025 compensation for its top five executives, a routine requirement that now offers a rare glimpse into pay structures at a leading med‑tech firm.

The compensation data reveal a mixed picture. CEO Edward Pesicka earned $11.2 million, a modest 4 % increase driven largely by stock awards, while CFO Jonathan Leon saw a 30 % jump to nearly $3 million after receiving a $300,000 cash bonus for closing the divestiture. Median employee wages rose only 1 % to $41,005, widening the CEO‑pay ratio to 272 : 1. Such disparities are common in capital‑intensive sectors, but they also raise questions about pay‑for‑performance alignment, especially after a year of missed revenue goals and a scrapped Rotech acquisition.

Investors will evaluate these figures when they cast say‑on‑pay votes at the May 14, 2026 annual meeting. A strong shareholder endorsement, as seen in the prior year, could signal confidence in the company’s strategic pivot and talent‑retention plan. Conversely, heightened scrutiny of the widening pay gap may pressure Accendra to tighten its compensation philosophy or tie more of its equity awards to post‑divestiture performance metrics. The disclosure underscores a broader industry trend: med‑tech firms must balance lucrative executive incentives with transparent, equitable pay structures to satisfy both talent markets and activist investors.